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A distinct branch of the Mycobacterium tuberculosis W phylogenetic lineage
(W14 group) has been identified and characterized by various genotyping
techniques. The W14 group comprises three strain variants: W14, W23, and
W26, which accounted for 26 clinical isolates from the New York City metro-
politan area. The W14 group shares a unique IS6110 hybridizing banding
motif as well as distinct polymorphic GC-rich repetitive sequence and vari-
able number tandem repeat patterns. All W14 group members have high lev-
els of streptomycin resistance. When the streptomycin resistance rpsL target
gene was sequenced, all members of this strain family had an identical
mutation in codon 43. Patients infected with the W14 group were primarily of
non-Hispanic black origin (77%); all were US-born. Including HIV positivity,
84% of the patients had at least one known risk factor for tuberculosis.
With the advent of molecular techniques, tuberculosis
(TB) investigators have a powerful tool to further the under-
standing of the transmission and phylogenetic properties of
Mycobacterium tuberculosis. Molecular techniques have been
used to discriminate exogenous versus endogenous disease
(1-3), investigate suspected outbreaks (2,4-6) and cases of
laboratory cross-contamination (7-9), study transmission
within a defined geographic setting (10,11), and demonstrate
the occurrence of exogenous superinfection in immunocom-
petent and immunocompromised patients (12,13). 
Genotyping has facilitated identification and character-
ization of the W strain, a multidrug-resistant (MDR) clone
associated primarily with nosocomial transmission in hospi-
tals and detention facilities in New York City (NYC) in the
early 1990s (14-17). In such studies, molecular markers were
used to confirm and characterize the W strain outbreak and
to elucidate a plausible evolutionary scenario for the sequen-
tial acquisition of multidrug resistance (14,17,18). In a
recent study, when molecular techniques were applied in a
population-based setting, genotyping identified a drug-sus-
ceptible group of isolates (W4) that represents a distinct
branch of the W phylogenetic lineage. Members of this W4
group define a previously unidentified cluster of cases in a
community in northern New Jersey; the cluster likely
resulted from both historical and recent transmission (19).
Although the W-MDR strain from NYC is clearly distinct
from the drug-susceptible W4 group, both groups of isolates
evolved from a common ancestor (20).
Strains that define the W family have several distin-
guishing genotypes in common: 1) they belong to principal
genetic group 1 (17,21); 2) they have similar spoligotype pat-
terns, characterized by a deletion of spacers 1-34 and the cor-
responding repeat in the direct repeats (DR) region (19, 22-
24), an alteration that defines spoligopattern S00034 and
closely related spoligotypes; 3) they contain a unique inser-
tion in the origin of replication (19,20) and in the NTF locus
(20,25). Strains grouped in the W or Beijing family are prev-
alent in China, Southeast Asia (26,27), Russia, and other
former Soviet regions (unpub. data) and have recently been
reported in South Africa (23). 
By multiple genetic techniques, we investigated a clus-
ter of NYC  M. tuberculosis isolates (W14 group) that are
resistant to at least streptomycin and share identical or
closely related DNA fingerprint patterns. Results from mul-
tiple typing methods were used to show the relatedness of
the three IS6110 fingerprint patterns, W14, W23, and W26
and their evolution. 
Materials and Methods
Mycobacterial Isolates and Patients
A total of 26 isolates from 26 patients were identified
and grouped based on their IS6110 fingerprint patterns. The
IS6110 fingerprint archive at the Public Health Research
Institute Tuberculosis Center (PHRI TB Center) includes
fingerprint patterns from >13,000  M. tuberculosis clinical
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specimens characterized since 1992. More than 80% of the
isolates were cultured from NYC and New Jersey cases;
remaining samples are from seven other states and interna-
tional sources. 
The W14 group isolates are part of a NYC convenience
sample, which represents 44% (n=6,655) of the total number
of culture- positive TB cases reported in 1992-1999
(~15,000). Isolates were collected for numerous outbreak,
surveillance, and research studies (14,17,28-31). Basic clini-
cal, demographic, and routine contact-tracing information
was obtained for 22 of the 26 patients; data for 21 cases were
obtained from the NYC Tuberculosis Control Program sur-
veillance database; the one exception was from the New Jer-
sey Department of Health and Senior Services. Isolates
originated from 16 institutions, including NYC hospitals and
correctional facilities. Laboratory cross-contamination was
ruled out since none of the clinical specimens were cultured
or processed during the same time period, and all patients
had well-documented TB.
IS6110 DNA Fingerprinting and Pattern Interpretation
M. tuberculosis isolates were cultured on Lowenstein-
Jensen slants and grown at 37oC for 3 to 5 weeks. IS6110
DNA fingerprint analyses were performed according to a
standard method using both the 5' and 3' fragments of the
IS6110 genetic element (32). Hybridization patterns were
compared on a Sun Sparc5 Workstation by using the BioIm-
age Whole Band Analyzer software version 3.4  (Genomic
Solutions, Ann Arbor, MI). The Jaccard matching method
and an unweighted pair group method that used arithmetic
averages and average linkage clustering identified related
patterns, in accordance with the protocol of the National
Tuberculosis Genotyping and Surveillance Network, Centers
for Disease Control and Prevention (CDC). Nomenclature of
the DNA fingerprint patterns was as follows: Isolates with
identical banding patterns were assigned the same arbitrary
letter code (e.g., W, J, AF). IS6110 patterns that resembled
but were not identical to one of these patterns were denoted
by addition of a number (e.g., W14, W23). 
Other Southern Blot Hybridization Probes: Polymorphic 
GC-Rich Repetitive Sequence and Direct Repeat
Chromosomal DNA was restricted with  Alu I and
hybridized with the polymorphic GC-rich repetitive sequence
(PGRS) probe (GenBank accession number M95490) (33).
Direct-repeat restriction fragment-length polymorphism
(RFLP) primers DRa and DRb were used to generate a DR
probe with H37Rv (strain ATCC 35177) as a template. The
DR amplicon was used as a probe to re-hybridize both mem-
branes (Pvu II and Alu I) previously generated for IS6110
and PGRS genotyping, respectively (34).
Spacer Oligonucleotide Genotyping (Spoligotyping)
Spoligotyping was performed according to the protocol
described by Kamerbeek et al. (34). The spoligotype of the 26
samples belonging to the W14 group was compared against a
spoligotype database maintained by the Wadsworth Center,
New York State Department of Health, comprising >2,500
clinical specimens. 
Variable Number of Tandem Repeats 
Tandem repeat loci ETR-A to ETR-E were amplified by
polymerase chain reaction (PCR) and analyzed by gel elec-
trophoresis to generate variable number of tandem-repeat
(VNTR) allele profiles, as described by Frothingham and
Meeker-O’Connell (35). Each digit of the allele profile repre-
sents the number of tandem-repeat copies at a particular
locus. The patterns were compared against the PHRI TB
Center VNTR database (~500 isolates) and profiles at the
Durham Veterans Affairs Medical Centers database (745 iso-
lates, 85 in the W phylogenetic lineage) (19). 
Streptomycin/Isoniazid/Rifampin/Ethambutol and 
Ethionamide Susceptibility Testing
Primary drug resistance to streptomycin/isoniazid
(INH)/rifampin/ethambutol (SIRE) was determined by using
TB susceptibility Quad Plate I and II (Remel No. 3501). M.
tuberculosis cultures were determined to be resistant to anti-
microbial agents at concentrations >1 µg/mL for INH and
rifampin, 7.5 µg/mL for ethambutol, and 10 µg/mL for strep-
tomycin. The MIC for streptomycin was determined for rep-
resentative samples according to standard methodology by
using the agar diffusion assay (36). Isolates were subcul-
tured onto 7H10/ADC medium (Difco, Detroit, MI) contain-
ing 2 to 500 µg/mL of streptomycin. The NYC Bureau of
Laboratories performed pyrazinamide (PZA) testing (37).
DNA Sequencing Streptomycin (rpsL) and INH (kat G) 
Resistance Genes
Analyses of the rpsL and katG genes were performed on
a MicroGene Clipper 2 Dye Automated DNA Sequencer (Vis-
ible Genetics, Toronto, Ontario, Canada). Sequencing in the
5' and 3' directions was carried out simultaneously by using
a two-dye system (Cy 5 and Cy 5.5; two-dye filter subsystem)
to confirm mutations. The primers used to generate ampli-
cons for sequencing were provided by Visible Genetics.
W-Strain Family Genotype
The principal genetic group was determined for each iso-
late as described (21). In addition, specific IS6110 insertion
site mapping probes were used to determine the presence of
insertions in the origin of replication and the NTF chromo-
somal region (20,25). The region flanking the deletion in the
DR locus commonly associated with the W family was ana-
lyzed by PCR amplification and comparative hybridization
(23). 
Results
The W Family Strain Collection
The W14 fingerprint pattern was identified in a data-
base of >13,000 clinical specimens representing approxi-
mately 9,000 patients and 3,563 distinct IS6110 fingerprint
patterns genotyped at the PHRI TB Center. From the total
IS6110 fingerprint patterns archived (N=3,563), 357 similar
yet distinct patterns representing 1,498 isolates were
grouped into the W family database by using standard
matching criteria. Twenty isolates had an identical hybrid-
ization pattern (W14); 6 other isolates shared closely related
IS6110 fingerprint patterns (3 W23 and 3 W26). These 26
isolates with three IS6110 patterns (W14, W23, and W26)Research
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form the W14 group, a subgroup within the W phylogenetic
lineage.
Molecular Features of W14 Group Isolates
The W14 group was originally defined on the basis of
IS6110 patterns. The group includes three closely related
fingerprints (W14, W23, and W26), with two characteristic
common motifs (denoted by brackets in Figure 1A). Motifs A
and B are unique to the W14 group. Southern blot hybridiza-
tion of the Pvu II membrane with the 5'-IS6110 probe con-
firmed that the difference in IS6110 pattern between W23
and W26 was the product of two independent IS6110 inser-
tions, rather than the outcome of a single RFLP event (Fig-
ure 1B). 
PGRS probing showed a distinct hybridization pattern
(P00026) for all 26 isolates in this group (Figure 1C). The
P00026 pattern was used to segregate the W14 group iso-
lates from all other clinical samples, including other W fam-
ily groups in a PGRS database of >600 isolates. 
Results from five chromosomal loci (ETR-A to ETR-E)
were combined as a VNTR allele profile. All isolates in the
W14 group had the VNTR allele profile 42445. This allele
profile was unique to the W14 group when compared with
the isolates from the PHRI TB Center VNTR database
(n=>500) and an independent collection archived in Durham
VA Medical Center database (n=745). Together, these data-
bases include 85 isolates of the W family, including isolates
from Asia, Africa, the former Soviet Union, and the United
States. However, the allele profile 42445 was closely related
to other patterns found in members of the W family. The
most common profile for the W family is 42435; all profiles
identified to date within the W family differed from this pro-
file by a single allele. These VNTR profiles include 32435,
42436, 42437, 4253, and the W14 group, which is defined by
42445 (19). Unlike other members of the W phylogenetic lin-
eage, the W14 group has a unique spoligotype arbitrarily
designated as S00069 (Figure 2). Spoligopattern S00069 dif-
fered from S00034 associated with other reported W family
members by the absence of spacer number 40. Patterns
obtained by rehybridizing the same membranes used for
IS6110 and PGRS fingerprinting with the DRab probe sug-
gested that the disruption of spacer 40 was not due to an
IS6110 insertion (Figure 3). An IS6110 insertion within
spacer 40 would have generated two DR hybridizing bands,
including one of a higher molecular weight, as found in
strain CDC1551 (Figure 3) (38). Pattern S00069 was unique
to the W14 group when compared with the Wadsworth spoli-
gotype database of >2,500 isolates. The disruption of spacer
40 did not affect either chromosomal flanking region. Hence,
in agreement with the S00034 spoligotype that groups all W
family isolates analyzed, the region upstream from spacer 35
was deleted in isolates with S00069.
All members of the W14 group have high-level resistance
(MIC>500 µg/mL) to streptomycin (STRR). In addition, one
W14 and one W23 isolate were resistant to INH (INHR), one
W14 was INHR and ethambutol (EMBR) resistant, two W14 iso-
lates were ethionamide (ETHR) resistant, and one W14 was
ETHR and pyrazinamide (PZAR) resistant (Figure 4). Except
for the 26 isolates in the W14 group, no W family isolate from a
U.S. case in our collection was streptomycin monoresistant. 
DNA sequencing of the gene commonly associated with
streptomycin resistance, the  rpsL gene, identified a single
mutation (codon 43: AAGﬁAGG; LysﬁArg) in all the 26
W14 group isolates in this study. Three isolates were resis-
Figure 1. Southern blot hybridization of Mycobacterium tuberculosis isolates. A) IS6110-3' was used as a hybridization probe. The bracketed
pattern motives regions are characteristic of the W14 family. A1 and NTF denote the bands corresponding to the IS6110 insertions in the
dnaA-dnaN region and the NTF locus, respectively. Lanes 1 and 9 are standard markers; lane 2: W-MDR from New York City (W index
strain); lane 3, 4, 5 and 7: members of the W14 family; lane 6: W76 and lane 8: laboratory control strain H37Ra. B) Southern blot hybridiza-
tion with IS6110-5' probe. W23 and W26 each have one additional band from W14, when hybridized with either the 3' or 5' IS6110 probe. C)
The polymorphic GC-rich repetitive sequence was used as a probe. The W14 group (W14; W23; W26) has a distinctive pattern when compared
to all other isolates typed by polymorphic GC-rich repetitive sequence probe.
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tant to INH. Sequence analysis of the katG gene in these iso-
lates revealed that the one INHR-W23 isolate had a genetic
alteration at codon 315 (AGCﬁACC; SerﬁThr), while the
two INH R-W14 isolates had the same single nucleotide inser-
tion generating a frameshift mutation at codon 283
(CTGﬁATG), which results in a termination upstream at
codon 310, previously unreported (Figure 4).  
All 26 isolates in the W14 group were linked to the W
family based on all the secondary typing methods used. All
had katG codon 463 sequence (CTG; Leu) and gyrA codon 95
sequence (ACC; Thr), placing them in genetic group 1 in the
broad evolutionary framework outlined by Sreevatsan et al.
(20,21). IS6110 insertion site mapping showed that all 26
isolates had the A1 insertion in the origin of replication and
a single IS6110 copy in the NTF chromosomal locus (20,25). 
Demographic Features of the W14 Cases
For the 22 patients in the W14 group, the mean age was
40 (range: 1 to 83 yrs) (Table). All were US-born, and 17
(77%) were of non-Hispanic black origin. In patients for
whom HIV serology data were available, 74% (14 of 19) were
HIV seropositive.  Including HIV serology, 84% (16 of 19) had
at least one of the known risk factors for TB (i.e., HIV, his-
tory of incarceration, homelessness, alcohol abuse, or intra-
venous drug use). A review of all drug-treatment regimen
records of the W14 cases showed that only one patient had
streptomycin as part of TB chemotherapy. 
Investigation of 18 cases from NYC identified 107 con-
tacts (mean of 6 contacts per case). Among contacts, 24%
were PPD (purified protein derivative) positive. Investiga-
tions conducted by the NYC TB Control Program did not link
any patients in this cohort or identify any new contacts with
active disease. 
Discussion
In this study the combination of multiple and indepen-
dent molecular typing techniques permitted the identifica-
tion and sub-grouping of a distinct branch of the W
phylogenetic lineage, the W14 group. Twenty isolates with
an identical IS6110 pattern (W14) and an additional six
(three W23 and three W26) isolates with closely related
IS6110 fingerprint patterns were identified in a fingerprint
archive of >13,000 isolates. The W14 group was first typed to
the “W” family fingerprint database of 1,498 isolates and
then later subgrouped as a distinct branch of the W family.
Five independent molecular techniques were used to confirm
the distinctiveness of W14 isolates. The IS6110 fingerprint
pattern had two distinct motifs, unique within the PHRI
database (Figure 1A). In addition, VNTR, PGRS, and spolig-
otyping patterns distinguished the W14 group from all other
isolates analyzed by these methods in our collection, which
includes >1,000 VNTR results, 600 PGRS images, and
>2,500 spoligotype samples (Figure 1-3).
All isolates in the W14 group were resistant to high lev-
els of streptomycin (>500 µg/mL), 20 were mono-streptomy-
cin resistant, and the remaining 6 isolates were poly-
resistant. Sequencing analysis confirmed that all isolates
shared the same mutation in the rpsL gene in codon 43, a
mutation previously associated with high levels of strepto-
mycin resistance (MIC>500; (39). The genetic alteration that
directs the change of lysine to threonine in codon 43 of the
rpsL gene is one of the two most frequently reported muta-
tions associated with streptomycin resistance: Together, they
account for approximately 53% of streptomycin-resistant
Figure 2. Spacer oligonucleotide typing (spoligotyping) of  Mycobacterium tuberculosis. Positive hybridization with the 43 different spacer
probes is denoted by black squares. W14 group has a distinctive disruption in spacer 40. Row 1: H37Ra, spoligotype S00001; 2: W-MDR, New
York City isolate, spoligotype S00034; and 3: W14, spoligotype S000069. 
Figure 3. Southern blot hybridization with the DRab probe.  The
DRab probe was used to hybridize against the PvuII-digested chro-
mosomal DNA previously used for IS6110 fingerprinting. Members
of the W14 group had a single hybridizing band of a slight lower
molecular weight than that of other W variants. In contrast, strain
CDC1551, which is known to have an insertion within the direct-
repeat locus, yielded two hybridizing bands, including one of higher
molecular weight. Both hybridizing bands in strain CDC1551 can be
superimposed with the IS6110 patterns of this isolate. Research
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cases (40). Hence, this observation alone would not be suffi-
cient to determine clonal relatedness. However, in combina-
tion with the molecular grouping, the data strongly suggest
that these strains are clonal and are the progeny of a single
streptomycin-resistant predecessor. 
Treatment records showed that only one patient
received two months of streptomycin in combination with
INH and rifampin. This regimen was changed when suscep-
tibility data were available. The absence of streptomycin
exposure in the patients with the W14 group of isolates fur-
ther supports the thesis that each of these patients was
infected with a streptomycin-resistant isolate rather than
acquiring resistance while on therapy. 
There were 295 streptomycin mono-resistant isolates
from 295 patients reported in NYC during 1993 and 1995 to
1999; 49% of these were from foreign-born patients. Of the
150 U.S.-born patients with mono-streptomycin resistant TB
reported in NYC during the same period, 83 isolates were
genotyped (55%); 31% (n=26) belonged to the W14 group.
Genotyping data of 187 mono-streptomycin-resistant clinical
isolates, including the 83 from NYC, identified the W14
group as the only epidemiologically important cluster of
patients. Six additional, unrelated clusters of two cases each
were identified in the PHRI fingerprint database. From the
PHRI archive, no streptomycin-susceptible isolates with the
W14 molecular characteristics have been identified to date
from NYC or other locations (samples fingerprinted: n=
>12,000; NYC: n= >6,000). Taken together, the molecular
data point to the acquisition of streptomycin resistance
before dissemination of this strain into the community.
Several strains have continued to acquire additional sec-
ondary drug resistances (Figure 4), including INH, ETH,
PZA, and EMB (W14: 1 STRR INHR, 1 STRR INHR EMBR, 2
STRR ETHR, 1 STRR PZAR ETHR; W23: 1 STRR INHR).
None of the isolates examined acquired resistance to
rifampin. In a previous study, we elucidated a plausible
pathway for the evolution of the W-MDR strain in NYC (W-
index strain) in the early 1990s (17). In that study, the emer-
gence and spread of the W-MDR strain in NYC was believed
to have started by acquisition of streptomycin resistance, fol-
lowed by INH and rifampin resistance, but the outbreak did
not occur until the MDR-genotype was developed. In con-
trast, the W14 group of isolates spread after streptomycin
resistance was acquired; subsequently, additional resistance
developed, creating a group of poly-resistant variants.
Sequencing data in combination with IS6110 Southern blot
hybridization were used to demonstrate that INH resistance
had developed on two occasions independently, once in W14
and once in a W23 (Figure 4) isolate. The W23 katG substitu-
tion on codon 315 is found on the same codon as in the W-
MDR index strain but involves a different nucleotide. DNA
sequence analysis of different resistance target genes pro-
vides molecular markers to speculate the stepwise building
of polyresistant strains. 
Since the late 1980s, molecular methods have been grad-
ually integrated into the study of TB epidemiology and con-
trol. In addition to augmenting conventional epidemiologic
investigations, molecular typing has been used to identify
previously unrecognized point-source cases and in two
reports was used to confirm transmission in a social setting
(41,42). More recently, molecular typing with surveillance
data uncovered an epidemiologically significant strain clus-
ter (n=43), the W4 group, from New Jersey, that has no
apparent common point source or patient links (19). The con-
cordance of demographic and geographic data with molecu-
lar methods and the lack of concrete links in the W4 cases
suggest a combination of reactivation and recent transmis-
sion. Likewise in this study, despite the demographic, geo-
graphic and molecular grouping, we could not establish any
patient linkage in the W14 group. Nonetheless, the extent
and validity of the molecular data demonstrated that these
22 patients were infected with either the same strain (16
W14 cases) or one of two closely related isolates (3 W23 or 3
W26). 
This study has a number of limitations. PHRI’s collec-
tion from NYC reflects a convenience sample that is approxi-
mately 44% of the total number of culture-positive TB cases
reported to the NYC TB Control Program in 1992 to 1999. Of
the W14 group patients, all were U.S.-born, >70% were HIV
positive, and most (73%) were 25 to 50 years of age at diag-
nosis. Despite the demographic homogeneity in these
Table. Demographic characteristics of patients in W14 groupa
Characteristics N=22 (%)
Gender
 Male 13 (59)
 Female  9 (49)
Race
 Non-Hispanic black 17 (77)
 Hispanic white  4 (18)
 Asian  1 (5)
Age at diagnosis
 Median age (range) 38 (1-83)
 25-50 years 16 (73)
HIV serology
 Seropositive 14 (64)
 Seronegative  5 (23)
 Unknown  3 (13)
Country of birth
 US born 22 (100)
 Foreign born 0 (0)
Risk factors
 IVDUb  7 (32)
 Alcoholic  9 (41)
 Incarceration  2 (9)
 Homelessness  2 (9)
Year of case report
 1992  2 (9)
 1993  7 (32)
 1994  4 (18)
 1995  1 (4) 
 1996  3 (14)
 1997  3 (14)
 1998  0 (0)
 1999  2 (9)
aAll data are presented as number (percentage) except median age.
bIVDU = intravenous drug use. Research
Vol. 7, No. 5, September-October 2001 847 Emerging Infectious Diseases
patients, no epidemiologic links were established. Further-
more, the limited sampling suggests an actual denominator
of W14 group cases larger than reported in this study, which
aids in explaining the inability to establish epidemiologic
links in the patients. Patient interviews were initially con-
ducted as part of routine contact investigation; patients were
not reinterviewed once molecular cluster information was
available. Therefore, in-depth investigation of cases that
appeared from molecular and surveillance data to be related
was not available, which limits the inferences we can make
on the observed lack of epidemiologic links. 
Given the lack of overt epidemiologic links indicative of
recent transmission between cases, the possibility that the
W14 strain group is endemic to the region should be consid-
ered. However, the streptomycin monoresistance suggests
that this strain must have spread after the introduction and
application of this drug for TB treatment in 1944. It is sur-
prising that not a single susceptible, related strain has been
identified in the region even following extensive molecular
analysis of other W variants. If the W14 or its predecessor
were endemic, only the streptomycin-resistant variant has
managed to spread, again suggesting that this dissemination
depended on a single event, and yet, contact investigation
has failed to establish a link. We speculate that the W14
cluster with the large young HIV- seropositive population is
likely the result of recent transmission; however, the lack of
patient-to-patient links suggests a subgroup of cases caused
by an endemic strain that developed in NYC sometime after
streptomycin was introduced in 1944. 
By using multiple independent molecular markers, we
made inferences on the strains’ recent evolution. This study
highlights the importance of tracking all types of drug-resis-
tant strains to prevent the sequential development of multi-
drug-resistant strains. The utility that these methods lend to
TB control will rely on the efficiency of integrating both sur-
veillance and contact-tracing information with the molecular
data in a proactive manner for more well-informed TB inves-
tigations. 
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